|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNX14 |
Gene summary for SNX14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNX14 | Gene ID | 57231 |
| Gene name | sorting nexin 14 | |
| Gene Alias | RGS-PX2 | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9Y5W7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57231 | SNX14 | LZE4T | Human | Esophagus | ESCC | 1.29e-06 | 1.31e-01 | 0.0811 |
| 57231 | SNX14 | LZE5T | Human | Esophagus | ESCC | 2.10e-02 | 2.17e-01 | 0.0514 |
| 57231 | SNX14 | LZE24T | Human | Esophagus | ESCC | 6.10e-09 | 2.19e-01 | 0.0596 |
| 57231 | SNX14 | P1T-E | Human | Esophagus | ESCC | 2.88e-07 | 2.04e-01 | 0.0875 |
| 57231 | SNX14 | P2T-E | Human | Esophagus | ESCC | 1.43e-12 | 1.21e-01 | 0.1177 |
| 57231 | SNX14 | P4T-E | Human | Esophagus | ESCC | 1.17e-10 | 1.56e-01 | 0.1323 |
| 57231 | SNX14 | P5T-E | Human | Esophagus | ESCC | 1.67e-05 | 3.51e-02 | 0.1327 |
| 57231 | SNX14 | P8T-E | Human | Esophagus | ESCC | 7.99e-27 | 2.70e-01 | 0.0889 |
| 57231 | SNX14 | P9T-E | Human | Esophagus | ESCC | 3.63e-04 | 6.41e-02 | 0.1131 |
| 57231 | SNX14 | P10T-E | Human | Esophagus | ESCC | 2.96e-11 | 1.77e-01 | 0.116 |
| 57231 | SNX14 | P11T-E | Human | Esophagus | ESCC | 5.88e-12 | 5.71e-01 | 0.1426 |
| 57231 | SNX14 | P12T-E | Human | Esophagus | ESCC | 9.37e-09 | 1.09e-01 | 0.1122 |
| 57231 | SNX14 | P16T-E | Human | Esophagus | ESCC | 7.24e-05 | 8.73e-02 | 0.1153 |
| 57231 | SNX14 | P17T-E | Human | Esophagus | ESCC | 6.87e-06 | 3.37e-01 | 0.1278 |
| 57231 | SNX14 | P19T-E | Human | Esophagus | ESCC | 7.64e-03 | 1.91e-01 | 0.1662 |
| 57231 | SNX14 | P20T-E | Human | Esophagus | ESCC | 5.47e-10 | 2.05e-01 | 0.1124 |
| 57231 | SNX14 | P21T-E | Human | Esophagus | ESCC | 9.53e-22 | 5.11e-01 | 0.1617 |
| 57231 | SNX14 | P22T-E | Human | Esophagus | ESCC | 8.70e-07 | 1.50e-02 | 0.1236 |
| 57231 | SNX14 | P23T-E | Human | Esophagus | ESCC | 1.61e-12 | 1.51e-01 | 0.108 |
| 57231 | SNX14 | P24T-E | Human | Esophagus | ESCC | 3.46e-10 | 1.81e-01 | 0.1287 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:00973523 | Esophagus | ESCC | autophagosome maturation | 31/8552 | 40/18723 | 4.04e-05 | 3.26e-04 | 31 |
| GO:00162365 | Liver | NAFLD | macroautophagy | 45/1882 | 291/18723 | 2.31e-03 | 2.19e-02 | 45 |
| GO:001623621 | Liver | HCC | macroautophagy | 204/7958 | 291/18723 | 8.66e-22 | 1.41e-19 | 204 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:00973521 | Liver | HCC | autophagosome maturation | 30/7958 | 40/18723 | 3.04e-05 | 3.12e-04 | 30 |
| GO:00162366 | Lung | IAC | macroautophagy | 51/2061 | 291/18723 | 5.30e-04 | 7.49e-03 | 51 |
| GO:00224118 | Lung | IAC | cellular component disassembly | 68/2061 | 443/18723 | 2.89e-03 | 2.60e-02 | 68 |
| GO:001623612 | Lung | AIS | macroautophagy | 46/1849 | 291/18723 | 9.21e-04 | 1.23e-02 | 46 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:001623610 | Oral cavity | OSCC | macroautophagy | 192/7305 | 291/18723 | 7.01e-21 | 1.14e-18 | 192 |
| GO:003298410 | Oral cavity | OSCC | protein-containing complex disassembly | 136/7305 | 224/18723 | 3.42e-11 | 1.13e-09 | 136 |
| GO:00973522 | Oral cavity | OSCC | autophagosome maturation | 28/7305 | 40/18723 | 7.00e-05 | 5.60e-04 | 28 |
| GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
| GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
| GO:003298414 | Oral cavity | LP | protein-containing complex disassembly | 83/4623 | 224/18723 | 2.38e-05 | 3.86e-04 | 83 |
| GO:009735211 | Oral cavity | LP | autophagosome maturation | 21/4623 | 40/18723 | 1.42e-04 | 1.64e-03 | 21 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNX14 | SNV | Missense_Mutation | c.2777N>G | p.Gln926Arg | p.Q926R | Q9Y5W7 | protein_coding | tolerated(0.19) | benign(0.075) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNX14 | SNV | Missense_Mutation | c.1732C>A | p.Pro578Thr | p.P578T | Q9Y5W7 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNX14 | SNV | Missense_Mutation | c.1234G>C | p.Asp412His | p.D412H | Q9Y5W7 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNX14 | SNV | Missense_Mutation | rs750787317 | c.713G>T | p.Arg238Ile | p.R238I | Q9Y5W7 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNX14 | SNV | Missense_Mutation | novel | c.2588N>A | p.Arg863His | p.R863H | Q9Y5W7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-S3-A6ZH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| SNX14 | insertion | Nonsense_Mutation | novel | c.278_279insGTG | p.Glu93_Leu94insTer | p.E93_L94ins* | Q9Y5W7 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| SNX14 | insertion | Frame_Shift_Ins | novel | c.277_278insCCCT | p.Glu93AlafsTer9 | p.E93Afs*9 | Q9Y5W7 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| SNX14 | insertion | In_Frame_Ins | novel | c.304_305insTTTTCATCTTTATGA | p.Ala102delinsValPheIlePheMetThr | p.A102delinsVFIFMT | Q9Y5W7 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SNX14 | SNV | Missense_Mutation | novel | c.239T>A | p.Phe80Tyr | p.F80Y | Q9Y5W7 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SNX14 | SNV | Missense_Mutation | novel | c.404N>T | p.Ala135Val | p.A135V | Q9Y5W7 | protein_coding | deleterious(0.05) | possibly_damaging(0.846) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |